Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ocuphire Pharma Inc (OCUP)

Ocuphire Pharma Inc (OCUP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,831
  • Shares Outstanding, K 20,807
  • Annual Sales, $ 590 K
  • Annual Income, $ -56,690 K
  • 60-Month Beta 0.45
  • Price/Sales 114.10
  • Price/Cash Flow N/A
  • Price/Book 5.60
Trade OCUP with:

Options Overview Details

View History
  • Implied Volatility 207.12% ( +52.03%)
  • Historical Volatility 78.03%
  • IV Percentile 87%
  • IV Rank 37.70%
  • IV High 548.78% on 09/23/22
  • IV Low 0.39% on 08/22/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 54
  • Volume Avg (30-Day) 195
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 1,094
  • Open Int (30-Day) 3,840

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.28
  • Number of Estimates 1
  • High Estimate -0.28
  • Low Estimate -0.28
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.08 +55.29%
on 11/07/22
3.50 -7.71%
on 12/02/22
+1.04 (+47.49%)
since 11/04/22
3-Month
1.90 +70.00%
on 09/23/22
3.50 -7.71%
on 12/02/22
+1.00 (+44.84%)
since 09/02/22
52-Week
1.78 +81.45%
on 06/16/22
4.43 -27.09%
on 03/25/22
-0.34 (-9.52%)
since 12/03/21

Most Recent Stories

More News
Ocuphire Pharma, Inc. (OCUP) Just Flashed Golden Cross Signal: Do You Buy?

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

OCUP : 3.21 (-1.53%)
All You Need to Know About Ocuphire Pharma, Inc. (OCUP) Rating Upgrade to Buy

Ocuphire Pharma, Inc. (OCUP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OCUP : 3.21 (-1.53%)
Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July

Mina Sooch CEO to Present at Ophthalmic Innovation Panel at the 11th Annual AECOS Summer Symposium and OIS Retina Innovation Summit ASRS Late-Breaking...

OCUP : 3.21 (-1.53%)
Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication

Newly Issued Patent Broadens Medical Uses of Oral APX3330 Therapy in Patients with Diabetes and Extends Expiry Thru 2038 Peer-Reviewed Publication...

OCUP : 3.21 (-1.53%)
10 Penny Stocks with > 1,000% Upside

Rising interest rates, sky-high inflation, and geopolitical concerns have dragged down the S&P 500 (SPX) and NASDAQ Composite (NDX) into bear market territory. While all this sounds rather doom and gloom,...

AMTI : 1.0650 (-9.75%)
ANGN : 0.8700 (-5.43%)
CKPT : 0.5650 (-2.59%)
EFTR : 0.4370 (-0.25%)
FRLN : 0.6002 (-3.19%)
GLYC : 2.24 (-2.18%)
MGNX : 6.46 (-6.38%)
OCUP : 3.21 (-1.53%)
PHAS : 0.0700 (-30.00%)
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

Met FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo ...

OCUP : 3.21 (-1.53%)
Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update

Nyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months Successfully Enrolled 4 Late-Stage Trials for Nyxol and APX3330 in...

OCUP : 3.21 (-1.53%)
Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference

FARMINGTON HILLS, Mich., May 11, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...

OCUP : 3.21 (-1.53%)
Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

Meets Primary Endpoint With 58% Of Nyxol treated Subjects Returning to Baseline Pupil Diameter at 90 Minutes Compared to 6% of Placebo Subjects...

OCUP : 3.21 (-1.53%)
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update

Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial Data Catalysts in 2022:– Nyxol® MIRA-3...

OCUP : 3.21 (-1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 3.75
2nd Resistance Point 3.63
1st Resistance Point 3.44
Last Price 3.21
1st Support Level 3.13
2nd Support Level 3.01
3rd Support Level 2.82

See More

52-Week High 4.43
Fibonacci 61.8% 3.42
Last Price 3.21
Fibonacci 50% 3.11
Fibonacci 38.2% 2.79
52-Week Low 1.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar